Bloomberg first reported the existence of the proposed rule, which comes as the administration works to implement a wide-ranging plan to lower prescription medicine prices.
N ) and McKesson Corp mCK.
The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Details of the proposed rule have not yet been made public, but its title on the OMB site refers to removing the safe harbor protection for rebates from the anti-kickback law.If there are any changes around rebates they can adjust other aspects of the pricing model to ensure they are being paid fairly for the value they are adding, Gill wrote.The administration has placed blame on middlemen such as pharmacy benefits managers - which administer drug benefits for employers and health plans - and health insurers for driving up drug prices by demanding hefty rebates in exchange for the broadest access to patients.Our Standards: The Thomson Reuters Trust Principles.Department of Health and Human Services on Wednesday night sent the proposed rule to the OMB.
Health and Human Services and OMB did not immediately respond to requests for comment.
N ) and Express Scripts eSRX.
Shares of drug wholesalers such as AmerisourceBergen Corp (.
Start collecting up to 294 for every ounce of gold you own today!
Health and Human Services Secretary Alex Azar and Gottlieb have questioned whether rebates provided by drug manufacturers should remain protected by federal law.
O fell slightly on Thursday on the move.
Any all i do is win lyrics nicki minaj thoughts about what this might be?The move is the first concrete sign that the Trump administration has started to review the legal status of these rebates since Food and Drug Administration Commissioner Scott Gottlieb raised the idea early this year that they should not be exempted from anti-kickback law.President Donald Trump made lowering prescription drug prices a top priority during his 2016 presidential campaign.N and pharmacy benefit managers, including CVS Health Corp (.Im thinking that this pitch by Uncommon Wisdom Daily, a Division of Weiss Research Inc.In May, his administration unveiled a drug pricing blueprint that included broad proposals for lowering prices that largely spared pharmaceutical manufacturers and instead went after pharmacy benefits managers.JP Morgan analyst Lisa Gill said Wall Street overreacted to the proposal submitted on Wednesday because rebates are only one component of pharmacy benefits managers profit streams.This is a discussion topic or guest posting submitted by a Stock Gumshoe reader.Pharmaceutical stocks rose after the blueprints release.File photo - A customer waits at the counter of a CVS Pharmacy store in Pasadena,.S., May 2, 2016.